After three years of COVID-19 disruptions of varying levels of seriousness, as it stood in fall 2022, the hope was that 2023 could ̶ should ̶ be a period of more stable market conditions for medtechs.
With the pandemic, however, it seems nothing is certain. New US COVID-19 infection rates were still doggedly above a quarter of a million a week late in the year (CDC’s...